Skye Bioscience receives Nasdaq delisting notice for negative stockholders' equity

Skye Bioscience, Inc.

Stockholders' equity was ($497,307) as of June 30, 2026, below Nasdaq's $2.5M minimum requirement.
Company has until Oct 2, 2026 to submit a compliance plan; Nasdaq may grant extension to Feb 14, 2027.
Common stock continues trading on Nasdaq under 'SKYE'; no immediate effect on listing.
Company evaluating alternatives to regain compliance; no assurance of success.
Also disclosed proposed acquisition of Redx Pharma Limited (Transaction Agreement dated Aug 14, 2026).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.